Charmacy Pharmaceutical Co., Ltd. Class H (HK:2289)
:2289
Want to see HK:2289 full AI Analyst Report?
2289 Stock Chart & Stats
HK$7.31
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$7.31
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$4.20 - HK$7.40
Previous CloseN/A
Volume50.00K
Average Volume (3M)283.00
Market Cap
HK$590.76M
Enterprise ValueHK$1.85B
Total Cash (Recent Filing)HK$753.92M
Total Debt (Recent Filing)HK$2.09B
Price to Earnings (P/E)11.0
Beta-0.14
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield8.03%
Share Statistics
EPS (TTM)0.42
Shares Outstanding108,000,000
10 Day Avg. Volume100
30 Day Avg. Volume283
Financial Highlights & Ratios
PEG Ratio-1.25
Price to Book (P/B)1.15
Price to Sales (P/S)0.16
P/FCF Ratio2.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin ImprovementA multi-year rise in gross margin indicates improving unit economics, pricing or product mix in the distribution business. Sustained higher gross margins provide structural protection for operating profit and cash generation, making the business more resilient to cost pressure.
Improved Cash Generation (2025)A meaningful recovery to positive operating cash flow and strong 2025 free cash flow improves the company's ability to fund operations, pay dividends and service debt. If sustained, this structural improvement increases financial flexibility and reduces reliance on external funding.
Revenue Stability And Modest GrowthRelatively stable revenues with modest growth point to durable demand and a steady market position in pharmaceutical distribution. Predictable top-line performance supports operating planning and makes margin and cash-flow improvements easier to sustain over multiple quarters.
Bears Say
Rising Leverage And Balance-sheet RiskA sharp increase in debt and a materially higher debt-to-equity ratio elevate refinancing and solvency risk. With equity flat and ROE subdued, higher leverage reduces buffer against downturns, constrains strategic flexibility, and raises the cost of capital over the medium term.
Thin And Falling Net MarginsPersistently thin and declining net margins limit the company's ability to convert revenue into earnings and build equity. Low profitability reduces internal funding for capex and deleveraging, making the firm more sensitive to cost shocks and interest expense over the next several quarters.
Volatile Operating Cash FlowWide swings in operating cash flow undermine predictability of free cash flow and complicate capital allocation. Even with 2025 strength, inconsistency raises risk that cash available for debt repayment or dividends could fall quickly if working-capital or margin trends reverse.
Charmacy Pharmaceutical Co., Ltd. Class H News
2289 FAQ
What was Charmacy Pharmaceutical Co., Ltd. Class H’s price range in the past 12 months?
Charmacy Pharmaceutical Co., Ltd. Class H lowest stock price was HK$4.20 and its highest was HK$7.40 in the past 12 months.
What is Charmacy Pharmaceutical Co., Ltd. Class H’s market cap?
Charmacy Pharmaceutical Co., Ltd. Class H’s market cap is HK$590.76M.
When is Charmacy Pharmaceutical Co., Ltd. Class H’s upcoming earnings report date?
Charmacy Pharmaceutical Co., Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 90 days.
How were Charmacy Pharmaceutical Co., Ltd. Class H’s earnings last quarter?
Charmacy Pharmaceutical Co., Ltd. Class H released its earnings results on Mar 27, 2026. The company reported HK$0.249 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.249.
Is Charmacy Pharmaceutical Co., Ltd. Class H overvalued?
According to Wall Street analysts Charmacy Pharmaceutical Co., Ltd. Class H’s price is currently Overvalued.
Does Charmacy Pharmaceutical Co., Ltd. Class H pay dividends?
Charmacy Pharmaceutical Co., Ltd. Class H pays a Annually dividend of HK$0.489 which represents an annual dividend yield of 8.03%. See more information on Charmacy Pharmaceutical Co., Ltd. Class H dividends here
What is Charmacy Pharmaceutical Co., Ltd. Class H’s EPS estimate?
Charmacy Pharmaceutical Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Charmacy Pharmaceutical Co., Ltd. Class H have?
Charmacy Pharmaceutical Co., Ltd. Class H has 108,000,000 shares outstanding.
What happened to Charmacy Pharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?
Charmacy Pharmaceutical Co., Ltd. Class H reported an EPS of HK$0.249 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Charmacy Pharmaceutical Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2289
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Charmacy Pharmaceutical Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.96%
12-Months-Change
Fundamentals
Return on Equity
7.66%
Trailing 12-Months
Asset Growth
19.90%
Trailing 12-Months
Company Description
Charmacy Pharmaceutical Co., Ltd. Class H
Charmacy Pharmaceutical Co., Ltd. engages in the trading of pharmaceutical products in the People's Republic of China. The company offers western medicines, Chinese patent medicines, healthcare products, and related consulting services to downstream distributors and terminal chemists. It also operates Charmacy e-Medicine, a B2B e-commerce platform to place orders online and make inquiries and payments. The company was formerly known as Chuangmei Pharmaceutical Co., Ltd. and changed its name to Charmacy Pharmaceutical Co., Ltd. in July 2016. Charmacy Pharmaceutical Co., Ltd. was incorporated in 1984 and is headquartered in Shantou, the People's Republic of China.
Technical Analysis
China Health Group
―
Shanghai Pharmaceuticals Holding Co
―
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Medlive Technology Co., Ltd.
―